FLT3
Aptose Partners With NCI to Study Tuspetinib in MyeloMATCH Trials
NCI will include the multi-kinase inhibitor in the umbrella trial evaluating targeted therapy combinations in AML and MDS patients.
Aptose Launches Phase I/II Study of FLT3 Inhibitor in Newly Diagnosed AML
The firm will track the activity of the triplet broadly in AML patients, including in those with FLT3, NRAS, and TP53 mutations.
Hemogenyx to Use FLT3 Assay to Identify AML Patients for CAR T-Cell Trial
The firm expects to launch its Phase I trial of HEMO-CAR-T in FLT3-expressing AML patients at MD Anderson Cancer Center imminently.
Eilean Therapeutics to Evaluate FLT3 Inhibitor Lomonitinib in Beat AML Trial
The lomonitinib arm will include patients with FLT3-mutated relapsed or refractory acute myeloid leukemia.
Kura Oncology Begins Testing Menin Inhibitor With Standard Therapies in Phase I AML Trial
The KOMET-008 trial of ziftomenib combinations will involve AML patients harboring either NPM1 mutations or KMT2A rearrangements.